Menthol

Menthol

SCHEMBL2937643

CC1CCC(C(C)C)C(O)C1.O=P(O)(O)O

nearest known ligand 0.81

Full drug profile on Sugi Atlas →

Known targets — ChEMBL curated mechanism

TRPA1TRPM8

The experimentally established mechanism targets of Menthol. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.

Predicted protein targets (top 8)

geneUniProtsupporting neighboursconfidence
TRPM8 known ✓ Q7Z2W7 5/20 0.81
TRPA1 known ✓ O75762 2/20 0.81
EPHX1 P07099 3/20 0.49
KCNA5 P22460 1/20 0.44
TRPV1 Q8NER1 4/20 0.40
ALDH1A1 P00352 3/20 0.40
LMNA P02545 1/20 0.40
HPGD P15428 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
(+)-Menthol SCHEMBL10072505 0.90 TRPM8 (1.00) TRPM8TRPA1EPHX1KCNA5TRPV1
Racementhol SCHEMBL521946 0.90 TRPM8 (1.00) TRPM8TRPA1EPHX1KCNA5TRPV1
(+)-Menthol SCHEMBL12646785 0.90 TRPM8 (1.00) TRPM8TRPA1EPHX1KCNA5TRPV1
(+) Neomenthol SCHEMBL260049 0.90 TRPM8 (1.00) TRPM8TRPA1EPHX1KCNA5TRPV1
(+)-Menthol SCHEMBL9968934 0.90 TRPM8 (1.00) TRPM8TRPA1EPHX1KCNA5TRPV1
(+)-Menthol SCHEMBL15449169 0.90 TRPM8 (1.00) TRPM8TRPA1EPHX1KCNA5TRPV1
(+)-Menthol SCHEMBL13059620 0.90 TRPM8 (1.00) TRPM8TRPA1EPHX1KCNA5TRPV1
Isomenthol SCHEMBL677675 0.90 TRPM8 (1.00) TRPM8TRPA1EPHX1KCNA5TRPV1
Menthol SCHEMBL20771511 0.90 TRPM8 (1.00) TRPM8TRPA1EPHX1KCNA5TRPV1
(+)-Menthol SCHEMBL1709231 0.90 TRPM8 (1.00) TRPM8TRPA1EPHX1KCNA5TRPV1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6916463-B2 Oral products having an aesthetic layer THE PROCTER & GAMBLE COMPANY (US) 2005-07-12 US claimed
US-20040057910-A1 Oral products having an aesthetic layer THE PROCTER & GAMBLECOMPANY 2004-03-25 US claimed
CN-101909582-A Oral care delivery system with microcrystalline wax PROCTER & GAMBLE 2010-12-08 CN disclosed
EP-2227214-A1 ORAL CARE DELIVERY SYSTEM WITH MICROCRYSTALLINE WAX The Procter & Gamble Company (US) 2010-09-15 EP disclosed
WO-2009090566-A1 ORAL CARE DELIVERY SYSTEM WITH MICROCRYSTALLINE WAX THE PROCTER & GAMBLE COMPANY (US) 2009-07-23 WO disclosed
US-20090181071-A1 Oral Care Delivery System with Microcrystalline Wax THE PROCTER & GAMBLE COMPANY 2009-07-16 US disclosed
EP-1542649-B1 ORAL PRODUCTS HAVING AN AESTHETIC LAYER PROCTER & GAMBLE (US) 2008-04-30 EP disclosed
US-6916463-B2 Oral products having an aesthetic layer THE PROCTER & GAMBLE COMPANY (US) 2005-07-12 US disclosed
EP-1542649-A1 ORAL PRODUCTS HAVING AN AESTHETIC LAYER THE PROCTER & GAMBLE COMPANY (US) 2005-06-22 EP disclosed
WO-2004028499-A1 ORAL PRODUCTS HAVING AN AESTHETIC LAYER THE PROCTER & GAMBLE COMPANY (US) 2004-04-08 WO disclosed
US-20040057910-A1 Oral products having an aesthetic layer THE PROCTER & GAMBLECOMPANY 2004-03-25 US disclosed
EP-0725630-A1 FAST DISSOLVING DOSAGE FORMS CONTAINING MAGNESIUM ALUMINUM SILICATE AND MULTIPLE ACTIVE INGREDIENTS THE PROCTER & GAMBLE COMPANY (US) 1996-08-14 EP disclosed
WO-1995011671-A1 FAST DISSOLVING DOSAGE FORMS CONTAINING MAGNESIUM ALUMINUM SILICATE AND MULTIPLE ACTIVE INGREDIENTS THE PROCTER & GAMBLE COMPANY (US) 1995-05-04 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090181071-A1 Oral Care Delivery System with Microcrystalline Wax MCRS1, TAS2R39, MRPS27 TRPM8 3970/4885TRPA1 3423/4885EPHX1 946/4885
US-20040057910-A1 Oral products having an aesthetic layer CUTA, LPL, SUCLG1 TRPM8 2892/4885TRPA1 2710/4885EPHX1 103/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.